{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:31:50Z","timestamp":1790299910632,"version":"4.1.0"},"reference-count":27,"publisher":"American Society for Microbiology","issue":"12","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            New treatment modalities are needed for the treatment of infections due to multidrug-resistant\n            <jats:italic>Staphylococcus aureus. S. aureus<\/jats:italic>\n            capsular polysaccharide immune globulin (Altastaph) is a polyclonal immune globulin preparation that is being developed as adjunctive therapy for persons with\n            <jats:italic>S. aureus<\/jats:italic>\n            infections complicated by bacteremia. In a phase II, multicenter, randomized, double-blind, placebo-controlled trial, 40 subjects with documented\n            <jats:italic>S. aureus<\/jats:italic>\n            bacteremia received standard therapy plus either Altastaph at 200 mg\/kg of body weight in each of two infusions 24 h apart or placebo. During the 42-day observation period, antibody pharmacokinetics and safety were the primary characteristics studied. Information regarding the resolution of bacteremia and fever was also analyzed. Anti-type-5 and anti-type-8 capsular antibody levels peaked after the second infusion at 550 \u03bcg\/ml and 419 \u03bcg\/ml, respectively, and remained above 100 \u03bcg\/ml at day 28. A total of 316 adverse events were noted in 39 of 40 subjects. Infusion-related adverse events in Altastaph recipients were infrequent and similar to those among recipients of commercial intravenously administered immunoglobulin G products. Five of 21 (23%) subjects in the Altastaph group died, whereas 2 of 18 (11%) subjects in the placebo group died (\n            <jats:italic>P<\/jats:italic>\n            = 0.42). Compared to the control patients, the Altastaph recipients had a shorter median time to the resolution of fever (2 days and 7 days, respectively;\n            <jats:italic>P<\/jats:italic>\n            = 0.09) and a shorter length of hospital stay (9 days and 14 days, respectively;\n            <jats:italic>P<\/jats:italic>\n            = 0.03). However, these findings are exploratory, and there were few differences in the other variables measured. High levels of opsonizing antibodies were maintained for the initial 4 weeks. Although the study was not powered to show efficacy, these preliminary findings and safety profile suggest that Altastaph may be an effective adjunct to antibiotics and warrants further investigation (ClinicalTrials.gov number NCT00063089).\n          <\/jats:p>","DOI":"10.1128\/aac.00570-07","type":"journal-article","created":{"date-parts":[[2007,9,25]],"date-time":"2007-09-25T00:39:56Z","timestamp":1190680796000},"page":"4249-4254","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["Phase II, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial of a Polyclonal Anti-\n            <i>Staphylococcus aureus<\/i>\n            Capsular Polysaccharide Immune Globulin in Treatment of\n            <i>Staphylococcus aureus<\/i>\n            Bacteremia"],"prefix":"10.1128","volume":"51","author":[{"given":"Mark E.","family":"Rupp","sequence":"first","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, Nebraska"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"H. Preston","family":"Holley","sequence":"additional","affiliation":[{"name":"Nabi Biopharmaceuticals, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lutz","sequence":"additional","affiliation":[{"name":"St. Agnes Medical Center, Fresno, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Dicpinigaitis","sequence":"additional","affiliation":[{"name":"Montefiore Medical Center, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Woods","sequence":"additional","affiliation":[{"name":"Durham Veterans Affairs Medical Center, Durham, North Carolina"},{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald P.","family":"Levine","sequence":"additional","affiliation":[{"name":"Wayne State University, Detroit, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Veney","sequence":"additional","affiliation":[{"name":"Nabi Biopharmaceuticals, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Vance G.","family":"Fowler","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(84)90002-6"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jp.7211496"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajic.2004.10.001"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000091185.93122.40"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa025025"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000223517.98486.2f"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.64.5.1659-1665.1996"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.58.7.2367-2374.1990"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053783"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.17.2066"},{"key":"e_1_3_2_12_2","first-page":"1090","volume":"561","year":"1988","unstructured":"Karakawa, W., A. Sutton, R. Schneerson, A. Karpas, and W. Vann. 1988. Capsular antibodies induce type-specific phagocytosis of capsulated Staphylococcus aureus by human polymorphonuclear leukocytes. Infect. Immun.561:1090-1095.","journal-title":"Infect. Immun."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1286-4579(00)01292-2"},{"key":"e_1_3_2_14_2","first-page":"28","volume":"20","year":"1975","unstructured":"Krotova, T., M. Gerasimova, O. Koloshtivina, V. Kozlova, and V. Kuzmin. 1975. Use of antistaphylococcal polyglobulin and antistaphylococcal plasma in children with various staphylococcal diseases. Prob. Gematol. Pereliv. Krovi.20:28-31.","journal-title":"Prob. Gematol. Pereliv. Krovi."},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1106.040831"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.65.10.4146-4151.1997"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1086\/428616"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.15.1756"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.17.1.218-234.2004"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/345368"},{"key":"e_1_3_2_21_2","unstructured":"Nabi Biopharmaceuticals announces results of StaphVAX confirmatory phase III clinical trial 2005"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0501.990102"},{"key":"e_1_3_2_23_2","unstructured":"Ann. Meet. 2005"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/52.3-4.591"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011297"},{"key":"e_1_3_2_26_2","first-page":"256","volume":"23","year":"1996","unstructured":"Steinberg, J. P., C. C. Clark, and B. O. Hackman. 1996. Nosocomial and community-acquired Staphylococcus aureus bacteremia from 1980 to 1993: impact of intravascular devices and methicillin resistance. Clin. Infect. Dis.23:256-259.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00096-06"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00570-07","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00570-07","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:21:38Z","timestamp":1645471298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00570-07"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["10.1128\/AAC.00570-07"],"URL":"https:\/\/doi.org\/10.1128\/aac.00570-07","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12]]},"assertion":[{"value":"2007-05-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-09-13","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2007-12-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}